Tevogen Bio (TVGN) awards 40,000 restricted shares to director Feike

Rhea-AI Filing Summary

Feike Jeffrey L. reported acquisition or exercise transactions in this Form 4 filing.

Tevogen Bio Holdings Inc. director Jeffrey L. Feike received a grant of 40,000 shares of restricted common stock at $0.00 per share under the 2024 Omnibus Incentive Plan. The award vests in three equal installments tied to service-based anniversaries and aggregate revenue thresholds of $50 million, $100 million, and $150 million since the grant date. Following this grant, Feike directly holds 56,435 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Feike Jeffrey L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	--

Holdings After Transaction: Common Stock — 56,435 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock granted: 40,000 shares Grant price per share: $0.00 Shares held after grant: 56,435 shares +3 more

6 metrics

Restricted stock granted 40,000 shares Grant of restricted common stock to director Jeffrey L. Feike

Grant price per share $0.00 Price per share for the restricted stock grant

Shares held after grant 56,435 shares Total direct common stock holdings following the transaction

First revenue vesting threshold $50 million Aggregate revenue required since grant date for first vesting condition

Second revenue vesting threshold $100 million Aggregate revenue required since grant date for second vesting condition

Third revenue vesting threshold $150 million Aggregate revenue required since grant date for third vesting condition

Key Terms

restricted stock, 2024 Omnibus Incentive Plan, aggregate revenue, vesting date

4 terms

restricted stock financial

"Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2024 Omnibus Incentive Plan financial

"grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan"

aggregate revenue financial

"the Issuer having aggregate revenue of $50 million since the grant date"

vesting date financial

"provided that the reporting person remains in service with the Issuer on the applicable vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 05:30 PM Accepted by SEC EDGAR 07/10/2026 - 05:30 PM Learn about SEC filing dates

FAQ

What did Tevogen Bio (TVGN) director Jeffrey L. Feike report in this Form 4?

Jeffrey L. Feike reported a grant of 40,000 shares of restricted common stock of Tevogen Bio Holdings Inc., received as an equity award under the company’s 2024 Omnibus Incentive Plan.

What are the vesting conditions for the 40,000 restricted shares at Tevogen Bio (TVGN)?

The 40,000 restricted shares vest in three equal installments, tied both to service anniversaries and Tevogen Bio achieving aggregate revenue thresholds of $50 million, $100 million, and $150 million since the grant date.

Did Jeffrey L. Feike pay anything for the Tevogen Bio (TVGN) restricted stock grant?

No. The 40,000 restricted shares of Tevogen Bio common stock were granted at a price of $0.00 per share, reflecting a compensation-related equity award rather than an open-market purchase.

How many Tevogen Bio (TVGN) shares does Jeffrey L. Feike hold after this transaction?

After the grant, Jeffrey L. Feike directly holds 56,435 shares of Tevogen Bio common stock. This total includes the newly granted 40,000 restricted shares, which remain subject to vesting conditions.

What plan governs the restricted stock grant reported by Tevogen Bio (TVGN)?

The restricted stock grant to Jeffrey L. Feike was made under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which provides for equity-based compensation awards to eligible participants.

Is the Tevogen Bio (TVGN) restricted stock grant contingent on continued service?

Yes. Each vesting installment of the 40,000 restricted shares requires that Jeffrey L. Feike remain in service with Tevogen Bio on the applicable vesting date, in addition to the specified revenue milestones.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feike Jeffrey L.

(Last) (First) (Middle)

C/O TEVOGEN BIO HOLDINGS INC.

15 INDEPENDENCE BLVD, STE 410

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tevogen Bio Holdings Inc. [ TVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		A		40,000(1)	A	$0.00	56,435	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.

	/s/ Kirti Desai, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)